Jumping translocations and high-risk myeloma.
Morgan GJ et al. Blood. 2014 Apr 17;123(16):2442-3. doi: 10.1182/blood-2014-02-555755.
NF-Kappa B Modulation Is Involved in Celastrol Induced Human Multiple Myeloma Cell Apoptosis.
Ni H et al. PLoS One. 2014 Apr 22;9(4):e95846. doi: 10.1371/journal.pone.0095846. eCollection 2014.
Next-generation sequencing of peripheral B-lineage cells pinpoints the circulating clonotypic cell pool in multiple myeloma.
Thiele B et al. Blood. 2014 Apr 21. [Epub ahead of print].
Design, synthesis and biological evaluation of peptidyl epoxyketone proteasome inhibitors composed of β-amino acids.
Zhang J et al. Chem Biol Drug Des. 2014 Apr 18. doi: 10.1111/cbdd.12342. [Epub ahead of print].
Bortezomib induces thrombocytopenia by the inhibition of proplatelet formation of megakaryocytes.
Murai K et al. Eur J Haematol. 2014 Apr 21. doi: 10.1111/ejh.12342. [Epub ahead of print].
Novel therapeutic targets in myeloma bone disease.
Webb SL et al. Br J Pharmacol. 2014 Apr 21. doi: 10.1111/bph.12742. [Epub ahead of print].
Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues.
Sanvoranart T et al. Biochem Biophys Res Commun. 2014 Apr 18. pii: S0006-291X(14)00685-8. doi: 10.1016/j.bbrc.2014.04.044. [Epub ahead of print].
Immunophenotype of normal and myelomatous plasma-cell subsets.
Robillard N et al. Front Immunol. 2014 Mar 31;5:137. doi: 10.3389/fimmu.2014.00137. eCollection 2014.
IL-6 Activated JAK/STAT3 Pathway and Sensitivity to Hsp90 Inhibitors in Multiple Myeloma.
Kolosenko I et al. Curr Med Chem. 2014 Apr 13. [Epub ahead of print].
piRNA-823 contributes to tumorigenesis by regulating de novo DNA methylation and angiogenesis in multiple myeloma.
Yan H et al. Leukemia. 2014 Apr 15. doi: 10.1038/leu.2014.135. [Epub ahead of print].
Toll-Like Receptors in Human Multiple Myeloma: New Insight into Inflammation-Related Pathogenesis.
Abdi J et al. Curr Mol Med. 2014 Apr 14. [Epub ahead of print].
High prevalence of immunoglobulin light chain gene aberrations as revealed by FISH in multiple myeloma and MGUS.
Türkmen S et al. Genes Chromosomes Cancer. 2014 Apr 12. doi: 10.1002/gcc.22175. [Epub ahead of print].
Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells.
Roy SS et al. Cancer Chemother Pharmacol. 2014 Apr 12. [Epub ahead of print].
Upregulation of Cx43 Expression in Bone Marrow Mesenchymal Stem Cells Plays a Crucial Role in Adhesion and Migration of Multiple Myeloma Cells.
Zhang X et al. Leuk Lymphoma. 2014 Apr 11. [Epub ahead of print].
TPL2 kinase regulates the inflammatory milieu of the myeloma niche.
Hope C et al. Blood. 2014 Apr 10. [Epub ahead of print].
The osteoblastogenesis potential of adipose mesenchymal stem cells in myeloma patients who had received intensive therapy.
Lin HH et al. PLoS One. 2014 Apr 10;9(4):e94395. doi: 10.1371/journal.pone.0094395. eCollection 2014.
The growing link between multiple myeloma and myeloid derived suppressor cells.
Tadmor T et al. Leuk Lymphoma. 2014 Apr 10. [Epub ahead of print].
The 19S Deubiquitinase Inhibitor b-AP15 is Enriched in Cells and Elicits Rapid Commitment to Cell Death.
Wang X et al. Mol Pharmacol. 2014 Apr 8. [Epub ahead of print].
MNK1-Induced eIF-4E Phosphorylation in Myeloma Cells: A Pathway Mediating IL-6-Induced Expansion and Expression of Genes Involved in Metabolic and Proteotoxic Responses.
Shi Y et al. PLoS One. 2014 Apr 8;9(4):e94011. doi: 10.1371/journal.pone.0094011. eCollection 2014.
MLN4924, an investigational NAE inhibitor, suppresses AKT and mTOR signaling pathway through up regulating REDD1 in human myeloma cells.
Gu Y et al. Blood. 2014 Apr 8. [Epub ahead of print].
Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients.
Busch A et al. Clin Exp Immunol. 2014 Apr 9. doi: 10.1111/cei.12343. [Epub ahead of print].
Expression of cancer-testis antigen in multiple myeloma.
He L et al. J Huazhong Univ Sci Technolog Med Sci. 2014 Apr;34(2):181-5. doi: 10.1007/s11596-014-1255-7. Epub 2014 Apr 8.
Naive idiotope-specific B and T cells collaborate efficiently in the absence of dendritic cells.
Jacobsen J et al. J Immunol. 2014 May 1;192(9):4174-83. doi: 10.4049/jimmunol.1302359. Epub 2014 Apr 4.
Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.
Kikuchi J et al. Int J Hematol. 2014 Apr 6. [Epub ahead of print].
EEN regulates the proliferation and survival of multiple myeloma cells by potentiating IGF-1 secretion.
Huang EW et al. Biochem Biophys Res Commun. 2014 Apr 2. pii: S0006-291X(14)00587-7. doi: 10.1016/j.bbrc.2014.03.127. [Epub ahead of print].
Gabapentin inhibits bortezomib-induced mechanical allodynia through supraspinal action in mice.
Kitamura R et al. J Pharmacol Sci. 2014 Apr 17;124(4):502-10. Epub 2014 Mar 29.
A Single Nucleotide Polymorphism in SLC7A5 is Associated with Gastrointestinal Toxicity after High-Dose Melphalan and Autologous Stem Cell Transplantation for Multiple Myeloma.
Giglia JL et al. Biol Blood Marrow Transplant. 2014 Apr 3. pii: S1083-8791(14)00195-5. doi: 10.1016/j.bbmt.2014.03.022. [Epub ahead of print].
In vivo models of multiple myeloma (MM).
Sanchez E et al. Biochem Pharmacol. 2014 Apr 1. pii: S0006-2952(14)00200-7. doi: 10.1016/j.bcp.2014.03.013. [Epub ahead of print].
Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro.
Bolomsky A et al. Exp Hematol. 2014 Apr 2. pii: S0301-472X(14)00135-0. doi: 10.1016/j.exphem.2014.03.005. [Epub ahead of print].
Benzimidazole derivative, BMT-1, induces apoptosis in multiple myeloma cells via a mitochondrial-mediated pathway involving H+/K+-ATPase inhibition.
Yang T et al. Oncol Rep. 2014 Apr 2. doi: 10.3892/or.2014.3122. [Epub ahead of print].
Heparanase enhances myeloma progression via CXCL10 downregulation.
Barash U et al. Leukemia. 2014 Apr 4. doi: 10.1038/leu.2014.121. [Epub ahead of print].
Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents.
Saha MN et al. Br J Cancer. 2014 Apr 1. doi: 10.1038/bjc.2014.164. [Epub ahead of print].
Identification of novel pathogenic copy number aberrations in multiple myeloma: the Malaysian context.
Ivyna Bong PN et al. Mol Cytogenet. 2014 Apr 1;7(1):24. doi: 10.1186/1755-8166-7-24.
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.
Huang SY et al. Ann Hematol. 2014 Apr 1. [Epub ahead of print].
Associations of VEGF and VEGFR2 polymorphisms with increased risk and aggressiveness of multiple myeloma.
Brito AB et al. Ann Hematol. 2014 Apr 1. [Epub ahead of print].
Near-infrared fluorescent 9-phenylethynylpyronin analogues for bioimaging.
Pastierik T et al. J Org Chem. 2014 Apr 18;79(8):3374-82. doi: 10.1021/jo500140y. Epub 2014 Mar 31.
Polymorphism of CD44 Influences the Efficacy of CD34+ Cells Mobilization in Patients with Hematological Malignancies.
Szmigielska-Kaplon A et al. Biol Blood Marrow Transplant. 2014 Mar 27. pii: S1083-8791(14)00192-X. doi: 10.1016/j.bbmt.2014.03.019. [Epub ahead of print].
THE ROLE OF P-GLYCOPROTEIN IN DRUG RESISTANCE IN MULTIPLE MYELOMA.
Abraham J et al. Leuk Lymphoma. 2014 Mar 28. [Epub ahead of print].
Genetic Modification of T Cells Redirected towards CS1 Enhances Eradication of Myeloma Cells.
Chu J et al. Clin Cancer Res. 2014 Mar 27. [Epub ahead of print].
Inactivation of protein-phosphatase 2A causing hyperphosphorylation of autoantigenic paraprotein targets in MGUS/MM is due to an exchange of its regulatory subunits.
Preuss KD et al. Int J Cancer. 2014 Mar 27. doi: 10.1002/ijc.28864. [Epub ahead of print].
Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
Oh S et al. Ann Hematol. 2014 Mar 27. [Epub ahead of print].
The impact of long-term lenalidomide exposure on the cellular composition of bone marrow.
Brioli A et al. Leuk Lymphoma. 2014 Apr 22. [Epub ahead of print].